Menu Back toSession-1207-Drug-Diagnostic-Co-Development-and-Regulatory-Requirement-and-Challenges-for-Companion-Diagnostic-Test

The 7th DIA China Annual Meeting


Session 1207 Drug-Diagnostic Co-Development and Regulatory Requirement and Challenges for Companion Diagnostic Test

Session Chair(s)

Jinjie  Hu, PhD

Jinjie Hu, PhD

  • co-chair of FDAAA International Network committee; Senior Consultant
  • Biologics Consulting Group, United States

Companion Diagnosticfor Precision Medicine

Speaker(s)

Changhua  Chen

Changhua Chen

  • -
  • GCP CLINPLUS, China
Xiaomeng  Liu

Xiaomeng Liu

  • -
  • GCP Clinplus, China
Zhiyang  Zhang

Personalized Medicine The Role of Biomarker for Clinical Treatment Decision

Zhiyang Zhang

  • -
  • 3G Biotech, China
James  Creeden, DrMed, PhD

Regulatory Implications for Personalized Medicines and Companion Diagnostics

James Creeden, DrMed, PhD

  • Director Medical Science
  • Roche (china) Ltd., China
Juanjuan  An

Juanjuan An

  • CFDA, China

Contact us

For exhibition, advertising and hosting inquiry, please contact:
Jean XU: jxu@kellencompany.com, or Sofie Peeters: speeters@kellencompany.com
Tel: +86 10 5923 1096

For general inquiry, please contact DIA China office:
dia@diachina.org
Tel: +86 10 5704 2650